Harrell Investment Partners LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,211 shares of the medical research company's stock after selling 3,545 shares during the period. Harrell Investment Partners LLC's holdings in IQVIA were worth $1,624,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after purchasing an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board increased its holdings in IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after buying an additional 77,981 shares during the period. Invesco Ltd. increased its stake in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of IQVIA by 2.5% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after buying an additional 59,426 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on IQV shares. JPMorgan Chase & Co. lowered their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. HSBC cut IQVIA from a "buy" rating to a "hold" rating and lowered their target price for the company from $260.00 to $160.00 in a research note on Friday, April 25th. Robert W. Baird lowered their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Finally, Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $226.32.
Get Our Latest Research Report on IQVIA
IQVIA Stock Performance
IQV stock opened at $154.63 on Thursday. The business's 50-day moving average price is $147.79 and its two-hundred day moving average price is $176.74. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a market cap of $26.75 billion, a PE ratio of 21.07, a P/E/G ratio of 1.69 and a beta of 1.28. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The company's revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the company posted $2.54 earnings per share. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
